StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO – Get Free Report) in a research note issued on Thursday. The firm set a “sell” rating on the medical device company’s stock.
NeuroMetrix Stock Up 1.6 %
Shares of NURO opened at $4.14 on Thursday. NeuroMetrix has a 52-week low of $2.66 and a 52-week high of $5.60. The company has a market cap of $8.32 million, a PE ratio of -0.66 and a beta of 2.29. The business has a fifty day moving average of $3.70 and a 200 day moving average of $3.85.
NeuroMetrix (NASDAQ:NURO – Get Free Report) last released its earnings results on Tuesday, August 6th. The medical device company reported ($0.74) earnings per share for the quarter. The business had revenue of $0.77 million for the quarter. NeuroMetrix had a negative return on equity of 41.74% and a negative net margin of 181.04%.
NeuroMetrix Company Profile
NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.
Read More
- Five stocks we like better than NeuroMetrix
- What Are the FAANG Stocks and Are They Good Investments?
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- Airline Stocks – Top Airline Stocks to Buy Now
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for NeuroMetrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix and related companies with MarketBeat.com's FREE daily email newsletter.